MX2016006177A - Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia. - Google Patents
Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia.Info
- Publication number
- MX2016006177A MX2016006177A MX2016006177A MX2016006177A MX2016006177A MX 2016006177 A MX2016006177 A MX 2016006177A MX 2016006177 A MX2016006177 A MX 2016006177A MX 2016006177 A MX2016006177 A MX 2016006177A MX 2016006177 A MX2016006177 A MX 2016006177A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- immunotherapy
- engineering
- chemotherapy
- drug resistant
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 229940044683 chemotherapy drug Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000000735 allogeneic effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000002512 chemotherapy Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01074—Deoxycytidine kinase (2.7.1.74)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
La presente invención se relaciona con el uso de células terapéuticas alogénicas listas para utilizarse en inmunoterapia junto con quimioterapia para tratar pacientes con cáncer. En particular, la invención desarrolló un método para diseñar células T alogénicas resistentes a agentes terapéuticos. Los beneficios terapéuticos proporcionados por esta estrategia deberán intensificarse por los efectos sinergísticos entre quimioterapia e inmunoterapia. En particular, la presente invención se relaciona con un método para modificar células T al inactivar al menos un componente receptor de células T que codifica un gen y al modificar las células T para conferir resistencia al fármaco. La invención abre el camino a estrategias de inmunoterapia estándar y de adopción razonable para tratar cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361907874P | 2013-11-22 | 2013-11-22 | |
DKPA201470362 | 2014-06-17 | ||
PCT/EP2014/075317 WO2015075195A1 (en) | 2013-11-22 | 2014-11-21 | Method of engineering chemotherapy drug resistant t-cells for immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016006177A true MX2016006177A (es) | 2016-08-19 |
Family
ID=51059229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006177A MX2016006177A (es) | 2013-11-22 | 2014-11-21 | Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia. |
Country Status (11)
Country | Link |
---|---|
US (1) | US10813951B2 (es) |
EP (1) | EP3071687B1 (es) |
JP (1) | JP6976058B2 (es) |
KR (1) | KR102348577B1 (es) |
CN (1) | CN105765061A (es) |
AU (1) | AU2014351797B2 (es) |
BR (1) | BR112016011169A2 (es) |
CA (1) | CA2931267C (es) |
IL (1) | IL245725B (es) |
MX (1) | MX2016006177A (es) |
WO (1) | WO2015075195A1 (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
LT3066201T (lt) | 2013-11-07 | 2018-08-10 | Editas Medicine, Inc. | Su crispr susiję būdai ir kompozicijos su valdančiomis grnr |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
WO2016097231A2 (en) * | 2014-12-17 | 2016-06-23 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
CA2973525C (en) | 2015-01-26 | 2021-12-14 | Cellectis | Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy |
EP3804741A3 (en) * | 2015-02-24 | 2021-07-14 | Board of Regents, The University of Texas System | Selection methods for genetically-modified t cells |
JP7033453B2 (ja) * | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法 |
JP7186615B2 (ja) | 2015-09-03 | 2022-12-09 | ザ ユーエイビー リサーチ ファウンデーション | 遺伝子操作された薬物耐性t細胞およびその使用方法 |
CN108699116A (zh) | 2015-10-23 | 2018-10-23 | 哈佛大学的校长及成员们 | 用于基因编辑的演化的cas9蛋白 |
US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
US20190328783A1 (en) | 2016-04-15 | 2019-10-31 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
EP3429633B1 (en) | 2016-04-15 | 2021-02-24 | Cellectis | A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
US11466291B2 (en) | 2016-07-06 | 2022-10-11 | Cellectis | Sequential gene editing in primary immune cells |
KR101777252B1 (ko) | 2016-07-07 | 2017-09-12 | 대한민국(농림축산식품부 농림축산검역본부장) | T 세포의 prrsv 증식 억제능 평가 방법 |
KR101777256B1 (ko) | 2016-07-07 | 2017-09-12 | 대한민국(농림축산식품부 농림축산검역본부장) | T 세포의 병원체 감염 세포 독성능 평가 방법 |
CA3030003A1 (en) * | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
US11078481B1 (en) | 2016-08-03 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11078483B1 (en) | 2016-09-02 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for measuring and improving CRISPR reagent function |
WO2018068257A1 (zh) * | 2016-10-13 | 2018-04-19 | 北京艺妙神州医疗科技有限公司 | 通用型car-t细胞及其制备方法和用途 |
CA3039928A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
CA3040048A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
WO2018073391A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
WO2018115189A1 (en) | 2016-12-21 | 2018-06-28 | Cellectis | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
CN110832075A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11690873B2 (en) | 2017-03-31 | 2023-07-04 | Cellectis Sa | Universal chimeric antigen receptor T cells specific for CD22 |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
CN107177632B (zh) * | 2017-05-27 | 2020-02-07 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 |
EP3645036A1 (en) | 2017-06-30 | 2020-05-06 | Cellectis | Cellular immunotherapy for repetitive administration |
EP3654994B1 (en) * | 2017-07-18 | 2022-12-28 | CSL Behring Gene Therapy, Inc. | A modulatable switch for selection of donor modified cells |
WO2019020733A1 (en) | 2017-07-26 | 2019-01-31 | Cellectis | METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR) |
EP3658578A1 (en) * | 2017-07-26 | 2020-06-03 | Cellectis | Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection |
JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物 |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
AU2018396083A1 (en) | 2017-12-29 | 2020-05-21 | Cellectis | Method for improving production of CAR T cells |
US20230158070A1 (en) | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
SG11202010319RA (en) * | 2018-04-27 | 2020-11-27 | Iovance Biotherapeutics Inc | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
AU2019374102A1 (en) * | 2018-10-31 | 2021-06-17 | Humanigen, Inc. | Materials and methods for treating cancer |
AU2019417700A1 (en) * | 2018-12-23 | 2021-07-08 | Csl Behring L.L.C. | Donor T-cells with kill switch |
WO2020191243A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
AU2020415318A1 (en) | 2019-12-23 | 2022-07-14 | Cellectis | New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy |
DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
US20230228739A1 (en) | 2020-07-03 | 2023-07-20 | Cellectis S.A. | Method for determining potency of chimeric antigen receptor expressing immune cells |
WO2022018262A1 (en) | 2020-07-24 | 2022-01-27 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
EP4188954A1 (en) | 2020-07-31 | 2023-06-07 | Cellectis S.A. | Dual car-t cells |
EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
IL308012A (en) | 2021-04-30 | 2023-12-01 | Cellectis Sa | Anti-MUC1 for novel chimeric antigen receptors and genetically engineered immune cells for solid tumor immunotherapy |
AU2022277649A1 (en) | 2021-05-21 | 2023-11-30 | Cellectis S.A. | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
WO2023081767A1 (en) * | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
WO2024003334A1 (en) | 2022-06-30 | 2024-01-04 | Cellectis S.A. | Enhancing safety of t-cell-mediated immunotherapy |
CN117511882A (zh) * | 2022-08-03 | 2024-02-06 | 浙江大学医学院附属第一医院 | 一种通用型免疫效应细胞及其制备方法和应用 |
WO2024094775A1 (en) | 2022-11-03 | 2024-05-10 | Cellectis S.A. | Enhancing efficacy and safety of t-cell-mediated immunotherapy |
WO2024121385A1 (en) | 2022-12-09 | 2024-06-13 | Cellectis S.A. | Two-dose regimen in immunotherapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2882916T3 (es) | 2009-11-02 | 2021-12-03 | Univ Emory | Inmunoterapia resistente a medicamentos para tratamiento de un cáncer |
EP3276000A3 (en) * | 2012-05-25 | 2018-02-21 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
PL3105317T3 (pl) * | 2014-02-14 | 2019-02-28 | Cellectis | Komórki do immunoterapii zaprojektowane do celowania antygenu obecnego zarówno na komórkach odpornościowych, jak i komórkach patologicznych |
-
2014
- 2014-11-21 MX MX2016006177A patent/MX2016006177A/es unknown
- 2014-11-21 EP EP14827176.0A patent/EP3071687B1/en active Active
- 2014-11-21 JP JP2016533125A patent/JP6976058B2/ja active Active
- 2014-11-21 BR BR112016011169A patent/BR112016011169A2/pt not_active Application Discontinuation
- 2014-11-21 AU AU2014351797A patent/AU2014351797B2/en active Active
- 2014-11-21 WO PCT/EP2014/075317 patent/WO2015075195A1/en active Application Filing
- 2014-11-21 CA CA2931267A patent/CA2931267C/en active Active
- 2014-11-21 KR KR1020167016611A patent/KR102348577B1/ko active IP Right Grant
- 2014-11-21 CN CN201480064032.6A patent/CN105765061A/zh active Pending
- 2014-11-21 US US15/037,988 patent/US10813951B2/en active Active
-
2016
- 2016-05-19 IL IL245725A patent/IL245725B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AU2014351797A1 (en) | 2016-06-09 |
WO2015075195A1 (en) | 2015-05-28 |
IL245725B (en) | 2021-04-29 |
IL245725A0 (en) | 2016-07-31 |
US10813951B2 (en) | 2020-10-27 |
JP2016538861A (ja) | 2016-12-15 |
CN105765061A (zh) | 2016-07-13 |
KR20160103002A (ko) | 2016-08-31 |
EP3071687B1 (en) | 2019-07-31 |
US20160361359A1 (en) | 2016-12-15 |
EP3071687A1 (en) | 2016-09-28 |
JP6976058B2 (ja) | 2021-12-01 |
KR102348577B1 (ko) | 2022-01-06 |
CA2931267A1 (en) | 2015-05-28 |
AU2014351797B2 (en) | 2021-03-11 |
CA2931267C (en) | 2023-08-15 |
BR112016011169A2 (pt) | 2017-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016006177A (es) | Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia. | |
MX2017002852A (es) | Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas. | |
MX2016015363A (es) | Terapias de combinacion para el tratamiento de cancer. | |
MX2017013178A (es) | Terapia de combinacion para cancer. | |
MX2015006491A (es) | Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas. | |
IL287889A (en) | Administration of transgenic t cells for the treatment of central nervous system cancer | |
IN2015KN00414A (es) | ||
MX2019014761A (es) | Manejo de toxicidad para actividad antitumoral de cars. | |
NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
NZ719049A (en) | Cancer treatment with combination of plinabulin and taxane | |
MA33810B1 (fr) | Compositions pour traiter les nausées et vomissements à médiation centrale | |
MX2017005134A (es) | Tratamiento del cáncer con inmunoestimuladores. | |
MX2020010991A (es) | Composicion para la estimulacion ovarica controlada. | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
MX359210B (es) | Composición de combinación de pac-1 y tamoxifeno. | |
MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. | |
MX2015003968A (es) | Angiotensina en el tratamiento de condiciones cerebrales. | |
MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2019010982A (es) | Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos. | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
TN2013000333A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
MX2017015532A (es) | Terapia de combinacion pac-1. | |
IN2014MN01944A (es) |